Lower Risk of Cardiovascular Events in Patients with Clinical Atherosclerotic Cardiovascular Disease Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-Clinical ASCVD Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Clinical Atherosclerotic Cardiovascular Disease Population)
Authors:
Kim G. Smolderen1,2; Carlos-Mena Hurtado1; Victoria Divino3; Zhenxiang Zhao3; Yan Chen4; Joanna Boland4; Jinlin Song4; Briain O Hartaigh3; Andrea Traina3; Kerem Ozer3; Filip K. Knop5; Michael G. Nanna1